U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06796114) titled 'Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated with Tremelimumab and Durvalumab' on Jan. 10.
Brief Summary: Several cancer immunotherapies that target the PD-L1/PD-1 pathway (i.e., checkpoint inhibitors) show promising clinical activity in patients with HCC. In particular, atezolizumab selectively targets PD-L1 to prevent interaction with receptors PD-1 and B7-1, thus reversing T-cell suppression. Moreover, atezolizumab in combination with bevacizumab, a monoclonal antibody that targets VEGF and inhibits angiogenesis, is associated with an objective response rate of 27.3% (Cheng et al...